Pitcairn Co. Sells 801 Shares of Zoetis Inc. (NYSE:ZTS)

Pitcairn Co. lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 2.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 36,977 shares of the company’s stock after selling 801 shares during the quarter. Pitcairn Co.’s holdings in Zoetis were worth $6,025,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC increased its holdings in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. grew its holdings in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after buying an additional 166 shares in the last quarter. Dunhill Financial LLC grew its holdings in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares in the last quarter. Murphy & Mullick Capital Management Corp purchased a new stake in Zoetis in the 4th quarter valued at $44,000. Finally, Asset Planning Inc bought a new position in Zoetis during the 4th quarter valued at $58,000. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on ZTS shares. Barclays increased their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Morgan Stanley reduced their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Stifel Nicolaus decreased their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $215.90.

Insider Buying and Selling

In related news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,862 shares of company stock valued at $312,254. Corporate insiders own 0.16% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $163.59 on Thursday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market cap of $73.25 billion, a PE ratio of 29.91, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The firm’s 50-day simple moving average is $166.20 and its two-hundred day simple moving average is $173.98.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.22%. Zoetis’s payout ratio is 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.